Adagio Medical (ADGM) Income Statement (2023 - 2026)
Income Statement report data from Sep 30, 2023 to Mar 31, 2026 for Adagio Medical (ADGM).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jul 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||
Total Revenue | - | - | - | - | - | 130K (+160.00%) | 50K (-80.00%) | 250K (+733.33%) | 30K (-25.00%) | 40K |
Cost Of Revenue | - | 60K (+100.00%) | 30K (-91.18%) | 340K (+36.00%) | 250K (-39.02%) | 410K (+156.25%) | 160K (-76.47%) | 680K (+25.93%) | 540K (+116.00%) | 250K |
Costof Goods And Services Sold | - | 60K (+100.00%) | 30K (-91.18%) | 340K (+36.00%) | 250K (-39.02%) | 410K (+156.25%) | 160K (-76.47%) | 680K (+25.93%) | 540K (+116.00%) | 250K |
Gross Profit | - | -400.00K (+1233.33%) | -30.00K | - | -250.00K (-10.71%) | -280.00K (+180.00%) | -100.00K (-76.74%) | -430.00K (-17.31%) | -520.00K (+147.62%) | -210.00K |
Operating Expenses | ||||||||||
Research And Development | 2.74M (+22.32%) | 2.24M (-19.13%) | 2.77M (+40.61%) | 1.97M (-46.17%) | 3.66M (+200.00%) | 1.22M (-2.40%) | 1.25M (-56.45%) | 2.87M (-17.29%) | 3.47M (-21.49%) | 4.42M |
Selling General And Administrative | 2.46M (+39.77%) | 1.76M (-39.73%) | 2.92M (+21.67%) | 2.40M (-31.23%) | 3.49M (+19.11%) | 2.93M (-39.59%) | 4.85M (+43.92%) | 3.37M (-30.23%) | 4.83M (+8.54%) | 4.45M |
Operating Expenses | 5.20M (+28.08%) | 4.06M (-29.02%) | 5.72M (+21.19%) | 4.72M (-36.22%) | 7.40M (+62.28%) | 4.56M (-27.16%) | 6.26M (-9.41%) | 6.91M (-21.83%) | 8.84M (-3.07%) | 9.12M |
Depreciation And Amortization | 210K | - | 500K (+150.00%) | 200K (-25.93%) | 270K (-15.63%) | 320K (+433.33%) | 60K (-80.00%) | 300K (-9.09%) | 330K (+230.00%) | 100K |
Operating Income | ||||||||||
Operating Income | -5.20M (+28.40%) | -4.05M (-29.20%) | -5.72M (+21.19%) | -4.72M (-36.22%) | -7.40M (+67.42%) | -4.42M (-28.82%) | -6.21M (-6.76%) | -6.66M (-24.40%) | -8.81M (-2.97%) | -9.08M |
Ebit | -5.20M (+28.40%) | -4.05M (-29.20%) | -5.72M (+21.19%) | -4.72M (-36.22%) | -7.40M (+67.42%) | -4.42M (-28.82%) | -6.21M (-6.76%) | -6.66M (-24.40%) | -8.81M (-2.97%) | -9.08M |
EBITDA | -4.99M (+22.91%) | -4.06M (-22.22%) | -5.22M (+15.49%) | -4.52M (-36.61%) | -7.13M (+73.48%) | -4.11M (-33.17%) | -6.15M (-3.30%) | -6.36M (-25.00%) | -8.48M (-5.57%) | -8.98M |
Other Income / Expenses | ||||||||||
Interest Income | 110K (-15.38%) | 130K (+62.50%) | 80K (-20.00%) | 100K (-37.50%) | 160K (-5.88%) | 170K | - | - | - | - |
Interest Expense | 780K (0.00%) | 780K (+4.00%) | 750K (+4.17%) | 720K (+9.09%) | 660K (+50.00%) | 440K (+46.67%) | 300K (-60.53%) | 760K (+1.33%) | 750K (+53.06%) | 490K |
Net Interest Income | 110K (-15.38%) | 130K (+62.50%) | 80K (-20.00%) | 100K (-37.50%) | 160K (-5.88%) | 170K | - | - | - | - |
Other Non Operating Income | 70K (-65.00%) | 200K (+1900.00%) | 10K (-90.00%) | 100K | -50.00K | 70K (+600.00%) | 10K (0.00%) | 10K | -40.00K (-66.67%) | -120.00K |
Net Income | ||||||||||
Income Before Tax | - | -25.32M | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -6.99M (+111.18%) | -3.31M (-67.29%) | -10.12M (+156.20%) | -3.95M (-48.77%) | -7.71M | 3.61M | -8.23M (+43.63%) | -5.73M (-28.55%) | -8.02M (-25.46%) | -10.76M |
Net Income | -6.99M (+111.18%) | -3.31M (-67.29%) | -10.12M (+156.20%) | -3.95M (-48.77%) | -7.71M | 3.61M | -8.23M (+43.63%) | -5.73M (-28.55%) | -8.02M (-25.46%) | -10.76M |
Comprehensive Income Net Of Tax | -7.04M (-72.04%) | -25.18M (+149.06%) | -10.11M (+153.38%) | -3.99M (-48.65%) | -7.77M | 3.60M | -8.24M (+43.80%) | -5.73M (-28.46%) | -8.01M (-25.56%) | -10.76M |